$FREQ News
Last published 2y ago
- 2y agoFREQURGNVYGRSCMP+1NorthStar Appoints Peter Pfreundschuh to Board of ManagersBusiness WireNorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer
- 3y agoFREQKRROKorro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 MillionGlobeNewswireKorro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially value-creating
- 3y agoFREQKorro Bio and Frequency Therapeutics Announce Merger AgreementBusiness WireMerger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio's wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1
- 3y agoFREQFrequency Therapeutics Provides Business Updates and First Quarter 2023 Financial ResultsBusiness WireFrequency Therapeutics, Inc. (NASDAQ:FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced business updates and financial
- 3y agoFREQFrequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial ResultsBusiness WireFrequency Therapeutics, Inc. (NASDAQ:FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced business updates and financial
- 3y agoFREQFrequency Therapeutics to Participate at Upcoming March Investor ConferencesBusiness WireFrequency Therapeutics, Inc. (NASDAQ:FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced that interim Chief Executive
- 3y agoFREQFrequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing LossBusiness WireFX-322-208 Study Fails to Meet Primary Endpoint, Showing No Significant Separation in Speech Perception Between FX-322 and Placebo Company Will Now Focus on Advancing its Program in Remyelination for Multiple Sclerosis
- 3y agoFREQFrequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis ProgramBusiness WireGlobal Neurology Leaders to Support Development of a Potentially Restorative Treatment for MS as Program Advances Toward 2023 Regulatory Filing Company also Expands Regenerative Medicine Advisory Board with Addition of
- 3y agoFREQFrequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing LossBusiness WireRegenerative Treatment Designed to Increase Drug Exposure Through the Cochlea; Study Results Expected in H2 2023 Frequency's Lead Hearing Program, FX-322, on Track for Phase 2b Topline Results in Q1 2023 Frequency
- 3y agoFREQFrequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical ResultsBusiness WireDecember 13 Program to Review FX-322 Phase 2b Study and Endpoints, Physician Demand for Interventions to Treat Sensorineural Hearing Loss and Market Opportunity Frequency Therapeutics, Inc. (NASDAQ:FREQ), a
- 4y agoFREQFrequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial ResultsBusiness WireEnrollment Completed for Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss; Readout Expected in Q1 2023 Company on Track for Q4 Clinical Trial Start of its Second Hearing Restoration Program,
- 4y agoFREQFrequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing LossBusiness WireStudy of Therapeutic to Restore Hearing Aims to Show Speech Perception Improvements in Individuals with Noise-Induced or Permanent Sudden Sensorineural Hearing Loss Company Aligned with FDA on Speech Perception Primary
- 4y agoFREQFrequency Therapeutics to Participate in September Investor and Medical ConferencesBusiness WireFrequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced that members of its management team will participa
- 4y agoFREQFrequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial ResultsBusiness WireQ1 2023 Readout Planned for FX-322-208 Phase 2b Sensorineural Hearing Loss Study, with Enrollment Completion Anticipated in Q3 Q4 Enrollment Start Planned for Phase 1b Study of Second Hearing Restoration Program, FX-345 Company Advances Remyelinat
- 4y agoFREQGainey McKenna & Egleston Investigates The Officers And Directors Of Frequency Therapeutics, Inc. (FREQ)GlobeNewswireNEW YORK, July 08, 2022 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that it is investigating the officers and directors of Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ:FREQ) for potential breaches of fiduciary duties,
- 4y agoFREQFrequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment ConferenceBusiness WireFrequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Chr
- 4y agoFREQFrequency Therapeutics Provides Business Updates and First Quarter 2022 Financial ResultsBusiness WireFX-322-208 Phase 2b Study in Individuals with Acquired Sensorineural Hearing Loss Remains on Track for a Readout in Q4 2022 or Q1 2023 Reports Cash and Cash Equivalents of $124.8M, Providing Runway into 2024; Funds Enable Company to Meet Multiple Cli
- 4y agoFREQFrequency Therapeutics to Participate in B. Riley Securities' Neuro & Ophthalmology Investor ConferenceBusiness WireFrequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Chr
- 4y agoBBIGCASAENSVFREQ+1Thinking about buying stock in Casa Systems, Vinco Ventures, Nordic American Tanker, Enservco, or Frequency Therapeutics?PR NewswireNEW YORK, April 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CASA, BBIG, NAT, ENSV, and FREQ.
- 4y agoFREQFrequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial ResultsBusiness WireCompany Reports Steady Enrollment for FX-322-208 Phase 2b Study in Individuals with Sudden and Noise-Induced Sensorineural Hearing Loss; Topline Results Anticipated in Q4 2022 or Q1 2023 Continued Progress on Second Program for Hearing Restoration, F
- 4y agoFREQFrequency Therapeutics to Participate in Upcoming March 2022 Investor ConferencesBusiness WireFrequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Executive Officer David L.
- 4y agoFREQFrequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare ConferenceBusiness WireCompany to Review Milestones for its Phase 2b Study of FX-322, the Near-Term Clinical Plan for its Second Hearing Restoration Asset, FX-345, and Selection of a Lead Candidate for its Novel Multiple Sclerosis Program that Has Shown Potent Pre-Clinical Da
- 4y agoFREQFrequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in NoiseBusiness WireFrequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today shared the results from its FX-322-113 study, a
- 4y agoFREQFrequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial ResultsBusiness WireEnrollment Underway for FX-322-208 Phase 2b Study in Subjects with Sudden and Noise-Induced Sensorineural Hearing Loss; Aligns with FDA on Speech Perception as Primary Endpoint for FX-322 Studies Expands Pipeline with New Pre-Clinical Program for Hea
- 5y agoFREQFrequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple SclerosisBusiness WireManagement and Leading KOLs will Provide Detailed Review of Completed FX-322 Clinical Data in Subjects with Sensorineural Hearing Loss (SNHL), Supporting Design of FX-322-208 Phase 2b Study New Hearing Restoration Program Advances Toward Clinical Stu
- 5y agoFREQFrequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination ProgramBusiness WireAt Nov. 9 Event, Management and Key Opinion Leaders to Review Detailed FX-322 Clinical Study Results in Patients with Sensorineural Hearing Loss (SNHL) and Design of New FX-322-208 Phase 2b Study Company to Introduce a Second Hearing Restoration Prog
- 5y agoFREQFrequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary EndpointBusiness WireFX-322-208 is a Randomized, Placebo-Controlled Study to Evaluate Hearing Improvement in Subjects with Acquired SNHL Company to Host R&D Event on November 9th to Provide Detailed Review of Completed FX-322 Clinical Studies Supporting FX-322-208 Inclus
- 5y agoFREQFrequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time PointsBusiness WireIn Follow-Up to Phase 1b Learning Study (FX-322-111), Some Subjects with Sensorineural Hearing Loss Show Increased Speech Perception Up to Twelve Months After Dosing Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine c
- 5y agoFREQFrequency Therapeutics to Present at Upcoming Investor ConferencesBusiness WireFrequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer
- 5y agoFREQFrequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial ResultsBusiness WireCompany Plans to Commence New FX-322 Phase 2 Study in Q4 2021 in a Refined Population of Individuals with Sensorineural Hearing Loss (SNHL) Will Host R&D Event on November 9th to Provide Detailed Insights into FX-322 Clinical Data, Plans for Continue
- 5y agoACRXFREQOCGNMoore Kuehn, PLLC Encourages Investors of FREQ, ACRX, or OCGN to Contact Law FirmPR NewswireNEW YORK, June 18, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders cause
- 5y agoFREQFrequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor ConferencesBusiness WireFrequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer
- 5y agoFREQFrequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America's Externally-Led Patient-Focused Drug Development Meeting to Address Sensorineural Hearing LossBusiness WireFrequency Therapeutics, Inc., (NASDAQ:FREQ) today shared a statement from David L. Lucchino, Frequency's Chief Executive Officer, in support of the Hearing Loss Association of America (HLAA) and its efforts to advance the voice of the patient in leading
- 5y agoFREQFrequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial ResultsBusiness WireData From Recent FX-322 Clinical Readouts, Including New Data from Phase 1b Study in Presbycusis (Age-Related Hearing Loss), Further Clarify Acquired Sensorineural Hearing Loss Target Patient Populations and Future Study Design Company Anticipates I
- 5y agoFREQFrequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational ScienceBusiness WireLEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the expansion of its clinical development team with the addition of Jeffery T. Lichtenhan, Ph.D., a leading expert in hearing diagnostics a ...
- 5y agoFREQFrequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare ConferenceBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the 20th Annual Needham Virtual Healthcare Conference.
- 5y agoFREQFrequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2020 Financial ResultsBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the fourth quarter and year ended December 31, 2020.
- 5y agoFREQFrequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose RegimenBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse event ...
- 5y agoFREQFrequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322Business WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the publication of its FX-322 Phase 1/2 study results in Otology & Neurotology, a leading peer-reviewed journal focused on disorders of the ea ...
- 5y agoFREQFrequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product PlanningBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Kevin Franck, Ph.D., as Senior Vice President of Strategic Marketing and New Product Planning. Dr. Franck will lead pre-com ...
- 5y agoFREQFrequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing OfficerBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Quentin McCubbin, Ph.D., as chief manufacturing officer. Dr. McCubbin will oversee Company technical operations, leading dr ...
- 5y agoFREQFrequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 39th annual J.P. Morgan Healthcare conference.
- 5y agoFREQFrequency Therapeutics to Host Investor Event on the Potential for Restorative Treatments for Acquired Sensorineural Hearing LossBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced plans to host a virtual event and live Q&A session on Tuesday, January 19, 2021 at 8:00 am ET.
- 5y agoFREQFrequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial OfficerBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer. Mr. Pfreundschuh will oversee the Company’s financial strategy and ...
- 5y agoWKHSPEIXDEFREQ+2Cramer's lightning round: Workhorse has got momentumCNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
- 5y agoFREQSTEUFPTFrequency Therapeutics Provides Business Updates and Reports Third Quarter 2020 Financial ResultsBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the third quarter ended September 30, 2020.
- 6y agoFREQFrequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a AnalysisBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today provided an update to its strategy and clinical development program for FX-322, its lead product candidate for the treatment of acquired sensorineural h ...
- 6y agoFREQSTEUFPTHNGRFrequency Therapeutics Appoints Cynthia Feldmann to its Board of DirectorsBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Cynthia Feldmann to its Board of Directors.
- 6y agoFREQFrequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing LossBusiness WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the completion of enrollment of its Phase 2a study of FX-322 for sensorineural hearing loss (SNHL). The company anticipates obtaining full res ...
- 6y agoFREQFrequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322Business WireWOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today presented clinical results from a longer-term durability study of FX-322, showing that some patients with chronic sensorineural hearing loss had signifi ...